Aspirin-induced asthma (Q42859): Difference between revisions
From determinar.ia.br - Determine suas informações
Changed an Item |
Changed an Item |
||||||||||||||
| Property / Collection date | |||||||||||||||
13 August 2026
| |||||||||||||||
| Property / Collection date: 13 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Revision as of 09:35, 13 August 2026
In some asthma individuals, acetylsalicylic acid (aspirin®™) and other nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase 1 (COX-1) exacerbate the condition. This distinct clinical syndrome, called aspirin-induced asthma (AIA), is characterised by an eosinophilic rhinosinusitis, nasal polyposis, aspirin hypersensitivity, and asthma.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | CA23.20 |
||
| English | Aspirin-induced asthma |
In some asthma individuals, acetylsalicylic acid (aspirin®™) and other nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase 1 (COX-1) exacerbate the condition. This distinct clinical syndrome, called aspirin-induced asthma (AIA), is characterised by an eosinophilic rhinosinusitis, nasal polyposis, aspirin hypersensitivity, and asthma. |
Statements
CID11:CA23.20
0 references
dki-india-CA23.20
0 references
Concluído
0 references
13 August 2026
0 references
